Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06233799 · ClinicalTrials.gov registry record · Phase 3

Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder

A Phase 3 study of Methamphetamine-dependence and Methamphetamine Abuse, sponsored by National Institute on Drug Abuse (NIDA).

Recruiting
Registry status
Phase 3
Development phase
360
Enrollment target
11
Study locations

NCT06233799 is a Phase 3 study of Methamphetamine-dependence and Methamphetamine Abuse that is actively recruiting participants, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 360 participants, above the 86-participant average among 18 other Methamphetamine-dependence trials with a reported enrollment target (319% higher). The trial reports 11 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06233799, a Phase 3 study of Methamphetamine-dependence and Methamphetamine Abuse, is actively recruiting participants, sponsored by National Institute on Drug Abuse (NIDA).

RECRUITING
Registry status
Phase 3
Development phase
360 participants
Enrollment target
11
Study locations

Study Summary

The primary objective of this study is to evaluate the efficacy of extended release naltrexone plus bupropion XL (XR-NTX/BUP-XL) compared to matched injectable and oral placebo (iPLB/oPLB) in reducing methamphetamine (MA) use in individuals with moderate or severe methamphetamine use disorder (MUD) seeking to stop or reduce MA use.

Conditions Studied

Methamphetamine-dependence Methamphetamine Abuse

Interventions

  • DRUG extended-release naltrexone (XR-NTX)
  • DRUG extended release bupropion (BUP-XL) tablets (BUP-XL)
  • DRUG iPLB
  • DRUG oPLB

Study Locations (11)

California

  • University of California Los Angeles - Los Angeles
  • University of California at San Diego - San Diego

Arkansas

  • University of Arkansas for Medical Sciences - Little Rock

Indiana

  • Indiana University - Indianapolis

Kansas

  • University of Kansas Medical Center - Kansas City

Minnesota

  • University of Minnesota - Minneapolis

Oregon

  • CODA - Portland

South Carolina

  • MUSC/BHS - Pickens

Tennessee

  • University of Tennessee - Memphis

Trial Details

FieldValue
Enrollment Target 360 participants
Start Date 2024-07-01
Est. Completion 2027-04-30
Phase Phase 3

Sponsor

National Institute on Drug Abuse (NIDA)

335 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06233799

The ClinicalTrials.gov registry entry for NCT06233799 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 360 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 86-participant average among 18 other Methamphetamine-dependence trials with a reported enrollment target (319% higher). The listed sponsor is National Institute on Drug Abuse (NIDA), which has 335 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Methamphetamine-dependence appearing as the primary indexed condition, and to 4 interventions - of which extended-release naltrexone (XR-NTX) is the first listed.

NCT06233799 reports 11 study locations spanning 10 distinct geographic areas - top geographies include California, Arkansas, Indiana.

Frequently Asked Questions

What is clinical trial NCT06233799 about?

NCT06233799 is a clinical study titled "Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder". The primary objective of this study is to evaluate the efficacy of extended release naltrexone plus bupropion XL (XR-NTX/BUP-XL) compared to matched injectable and oral placebo (iPLB/oPLB) in reducing methamphetamine (MA) use in individuals with moderate or severe methamphetamine use disorder (MUD) ...

What is the current status of trial NCT06233799?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 360 participants. The study started on 2024-07-01. Estimated completion is 2027-04-30.

What conditions does trial NCT06233799 study?

This clinical trial studies the following conditions: Methamphetamine-dependence, Methamphetamine Abuse.

What interventions are being tested in trial NCT06233799?

The interventions under investigation include: extended-release naltrexone (XR-NTX) (DRUG), extended release bupropion (BUP-XL) tablets (BUP-XL) (DRUG), iPLB (DRUG), oPLB (DRUG).

Who is sponsoring clinical trial NCT06233799?

This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06233799 being conducted?

This trial has 11 study locations across Arkansas, California, Indiana, Kansas, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Methamphetamine-dependence

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Methamphetamine-dependence

All registered trials for this condition

Methamphetamine Abuse

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.